While the industry races to screen faster and bigger, at Iktos we’ve chosen a different path - we don’t screen, we design. Using generative AI, we create novel molecules tailored to the desired properties from the start. The true challenge, however, lies in making what we imagine at a reasonable cost and speed. By combining AI-driven design with synthetic feasibility prediction and automated chemistry, we’ve bridged the gap between virtual and real molecules. In this talk, we show how this approach redefines drug discovery - with tangible, made-in-the-lab examples.
Yann Gaston-Mathé, CoFounder and Chief Executive Officer, Iktos AI
